Sökning: WFRF:(Thunander Maria) >
Real-world cost-eff...
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective
-
- Jendle, Johan, 1963- (författare)
- Örebro University,Örebro universitet,Institutionen för medicinska vetenskaper,Orebro Univ, Sweden,Ossian Hlth Econ & Commun, Switzerland,Ossian Health Economics and Communications
-
- Ericsson, Åsa (författare)
- Novo Nordisk Scandinavia AB, Malmö, Sweden
-
- Ekman, Bertil (författare)
- Linköping University,Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Endokrinmedicinska kliniken
-
visa fler...
-
- Sjöberg, Stefan (författare)
- Department of Medicine, Karolinska Huddinge University Hospital, Stockholm, Sweden,Karolinska Huddinge Univ Hosp, Sweden
-
- Gundgaard, Jens (författare)
- Novo Nordisk A/S, Søborg, Denmark
-
- da Rocha Fernandes, João (författare)
- Novo Nordisk A/S, Søborg, Denmark
-
- Mårdby, Ann-Charlotte (författare)
- Novo Nordisk Scandinavia AB, Malmö, Sweden
-
- Hunt, Barnaby (författare)
- Ossian Health Economics and Communications, Basel, Switzerland,Ossian Hlth Econ & Commun, Switzerland
-
- Malkin, Samuel Jp (författare)
- Ossian Health Economics and Communications, Basel, Switzerland
-
- Thunander, Maria (författare)
- Lund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups
-
visa färre...
-
(creator_code:org_t)
- 2020-09-14
- 2020
- Engelska.
-
Ingår i: Journal of Medical Economics. - : Informa Healthcare. - 1369-6998 .- 1941-837X. ; 23:11, s. 1311-1320
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://www.tandfonl...
-
http://dx.doi.org/10... (free)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background and Aims: The ReFLeCT study demonstrated that switching to insulin degludec from other basal insulins was associated with reductions in glycated hemoglobin and hypoglycemic events in type 1 (T1D) and type 2 diabetes (T2D), and reductions in insulin doses in T1D. The aim of the present analysis was to assess the short- and long-term cost-effectiveness of switching to insulin degludec in Sweden.Methods: Short-term outcomes were evaluated over 1 year in a Microsoft Excel model, while long-term outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model. Cohort characteristics and treatment effects were sourced from the ReFLeCT study. Costs (in 2018 Swedish krona [SEK]) encompassed direct medical expenditure and indirect costs from loss of workplace productivity. In the long-term analyses, patients were assumed to receive insulin degludec or continue prior insulin therapy (primarily insulin glargine U100) for 5 years, before all patients intensified to once-daily degludec and mealtime aspart.Results: Switching to insulin degludec was associated with improved quality-adjusted life expectancy of 0.04 and 0.02 quality-adjusted life years (QALYs) over 1 year, and 0.16 and 0.08 QALYs over patient lifetimes, in T1D and T2D. Combined costs in T1D and T2D were estimated to be SEK 1 249 lower and SEK 1 181 higher over the short term, and SEK 157 258 and SEK 2 114 lower over the long term. Benefits were due to lower insulin doses in T1D, reduced rates of hypoglycemia and lower incidences of diabetes-related complications. Insulin degludec was associated with an incremental cost-effectiveness ratio of SEK 64 298 per QALY gained for T2D over 1 year and considered dominant for T1D and T2D in all other comparisons.Conclusions: Insulin degludec was projected to be cost-effective or dominant versus other basal insulins for the treatment of T1D and T2D in Sweden.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)
Nyckelord
- Cost
- cost-effectiveness
- insulin degludec
- Sweden
- type 1 diabetes
- type 2 diabetes
- Cost
- cost-effectiveness
- insulin degludec
- Sweden
- type 1 diabetes
- type 2 diabetes
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Jendle, Johan, 1 ...
-
Ericsson, Åsa
-
Ekman, Bertil
-
Sjöberg, Stefan
-
Gundgaard, Jens
-
da Rocha Fernand ...
-
visa fler...
-
Mårdby, Ann-Char ...
-
Hunt, Barnaby
-
Malkin, Samuel J ...
-
Thunander, Maria
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Hälsovetenskap
-
och Hälso och sjukvå ...
- Artiklar i publikationen
-
Journal of Medic ...
- Av lärosätet
-
Örebro universitet
-
Linköpings universitet
-
Lunds universitet